Boston Scientific (BSX)
(Delayed Data from NYSE)
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall second-quarter performance.
Buy 5 Surging Old Economy Stocks to Tap Market Rally
by Nalak Das
Five old economy stocks with strong near-term potential are: NEM, GE, PFE, PGR, BSX.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.
PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.
DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its second-quarter performance.
Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.
3 Reasons Why Growth Investors Shouldn't Overlook Boston Scientific (BSX)
by Zacks Equity Research
Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat, '24 View Up
by Zacks Equity Research
Merit Medical's (MMSI) second-quarter results reflect growth in earnings and revenues. Operating margin expands.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
by Zacks Equity Research
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.
Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?
by Urmimala Biswas
Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.
Are Options Traders Betting on a Big Move in Boston Scientific (BSX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Boston Scientific (BSX) stock based on the movements in the options market lately.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
by Zacks Equity Research
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.